This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Takeda Oncology" – news · newspapers · books · scholar · JSTOR(February 2009) (Learn how and when to remove this message)
Takeda Oncology
Company type
Subsidiary
Industry
Biotechnology, Pharmaceutical Company
Founded
1993
Defunct
N/A
Headquarters
Cambridge, MA, United States
Key people
Christophe Bianchi, President
Products
Velcade (bortezomib) for injection
Number of employees
1200 (approx.)
Parent
Takeda Pharmaceutical Company
Website
www.takedaoncology.com
Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.
Takeda Oncology's research, development and commercialization activities focused in two therapeutic areas: oncology and inflammation to develop a line of new product candidates. It was one of the first companies to systematically search for genes linked to disease,[1] although none of the drugs which it is marketing or has in clinical trial, with one partial exception, have been the results of that research.[1]
It is particularly known for bringing bortezomib (marketed as Velcade) through clinical trials to approval for treatment of patients with multiple myeloma by the U.S. FDA, but has a growing clinical development pipeline of other product candidates.
On May 14, 2008, Japanese company Takeda Pharmaceutical announced the completion of its acquisition of Millennium for US$25.00 per share in cash—a deal worth $8.8 billion. Takeda completed the acquisition through a tender offer and subsequent merger as a wholly owned subsidiary Millennium: The Takeda Oncology Company - with the name being simplified to Takeda Oncology in 2013.
^ abPollack, Andrew (2005-06-29). "Shift Seen Atop Takeda Oncology". New York Times. Retrieved 2008-02-23.
TakedaOncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary...
Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the TakedaOncology Company as one of the 100 best companies to work for in the United...
ARIAD Pharmaceuticals, Inc. was an American oncology company, now part of TakedaOncology, which was founded in 1991 by Harvey J. Berger, M.D. and headquartered...
in March 2023. Seattle Genetics has collaboration agreements with TakedaOncology Company (formerly Millennium) to develop and commercialize brentuximab...
by Altos Therapeutics and was under development by TakedaOncology. "Trazpiroben - TakedaOncology - AdisInsight". Whiting RL, Choppin A, Luehr G, Jasper...
from this source, which is in the public domain. "Millennium: The TakedaOncology Company". .millennium.com. 8 August 2014. Archived from the original...
Sarepta Therapeutics Sobi Spark Therapeutics Syneos Health Synlogic TakedaOncology UCB Vertex Pharmaceuticals Zealand Pharma NORD is engaged in partnerships...
early 2017, ARIAD was acquired by Takeda Pharmaceuticals, Ltd. for $5.2 billion, becoming part of TakedaOncology. In February 2017, Medinol, Inc. announced...
Pharmaceuticals (later Takeda) in 2005, where she was known for her transformational leadership. Notably, she was the first female board member of Takeda when appointed...
is an orally available selective aurora A kinase inhibitor developed by Takeda. It was investigated as a treatment for relapsed or refractory peripheral...
Release. Takeda Pharmaceutical Company Limited. 8 March 2013. "Takeda Submits Vedolizumab BLA". Drug Discovery and Development. 21 June 2013. "Takeda's New...
lung carcinoma (NSCLC) with the KRAS G12C mutation. In August 2020, Amgen, Takeda, and AbbVie, as part of a COVID-19 research and development (R&D) alliance...
Rockville, Maryland that focused on gastroenterology, ophthalmology, and oncology-related disorders. In 2018, the company was acquired by Mallinckrodt. Sucampo...
Cancer immunology (immuno-oncology) is an interdisciplinary branch of biology and a sub-discipline of immunology that is concerned with understanding the...
supervision of Professor Ernest Fraenkel. In 2013, Pirhaji worked shortly at TakedaOncology developing a pipeline for Next Generation Sequencing analysis for cancer...
Pharmaceuticals and market panitumumab in China. Amgen and Takeda have an agreement under which Takeda will develop and commercialise panitumumab in Japan....
medical director, Clinical Oncology Research. In 2002, Kashala transitioned to Millennium Pharmaceuticals, Inc., The TakedaOncology Company, where he was...
Mifamurtide (trade name Mepact, marketed by Takeda) is a drug against osteosarcoma, a kind of bone cancer mainly affecting children and young adults, which...
It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory...
Otsuka Holdings was Japan's No.2 drug maker by sales after industry leader Takeda Pharmaceutical Company. The IPO debuted at $2.4 billion, making it the largest...
and Europe, and is a boronic acid derivative. The drug was developed by Takeda. In the US, it is approved since November 2015, and in the EU since November...
recommended by the American Society of Clinical Oncology as well as the European Society of Medical Oncology. Screening in the United States of most often...
Global Information